Spread | 0.06 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 1.2 |
Open | 1.2 |
1-Year Change | 34.83% |
Day's Range | 1.07 - 1.24 |
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing disruptive therapeutics for the treatment of patients with cancer. The Company is engaged in the commercial development of a polyamine analogue for pancreatic cancer. Its product candidate includes SBP-101, which is a proprietary polyamine analogue that accumulates in the exocrine pancreas acinar cells due to its chemical structure. The Company is conducting Phase I a/I b study of the safety, efficacy and pharmacokinetics of SBP-101 administered in combination with two standard-of-care chemotherapy agents, gemcitabine and nab-paclitaxel.
BRIEF: For the nine months ended 30 September 2021, Panbela Therapeutics Inc revenues was not reported. Net loss increased 70% to $6.6M. Higher net loss reflects Research and Development - Balancing increase of 90% to $3.2M (expense), General and administrative -Bal increase of 69% to $2.5M (expense), Other income decrease from $55K (income) to $611K (expense).